If it will be a clean cut , just for HIV , we be done by now as a separate company..
But with all other things , especially cancers , they CANT just go all the way with anyone without extremely good reasons ..
In a way it is a blessing and the curse for the present shareholders ...
But I wish all other biotech are with the same problems ...
IMO as always.